2-AG 2-arachidonoylglycerol
Selected indexed studies
- 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. (AAPS J, 2006) [PMID:16808043]
- Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. (Pharmacol Ther, 2023) [PMID:36966972]
- Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. (Sci Adv, 2024) [PMID:39612328]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Endocannabinoid overload. (2010) pubmed
- The endocannabinoid 2-arachidonoylglycerol is released and transported on demand via extracellular microvesicles. (2025) pubmed
- 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. (2006) pubmed
- Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. (2023) pubmed
- Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. (2024) pubmed
- 2-Arachidonoylglycerol and the cannabinoid receptors. (2000) pubmed
- Chemical tools to modulate 2-arachidonoylglycerol biosynthesis. (2018) pubmed
- 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain. (2018) pubmed
- Targeting 2-arachidonoylglycerol signalling in the neurobiology and treatment of depression. (2021) pubmed
- Photorelease of 2-Arachidonoylglycerol in Live Cells. (2019) pubmed